SEI Investments
AVTX icon

SEI Investments’s Avalo Therapeutics AVTX Stock Holding History

SEI Investments’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Sell
17,931
-38,923
-68% -$615K ﹤0.01% 2818
2026
Q1 		$849K Buy
+56,854
New +$889K ﹤0.01% 2428

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

SEI Investments's AVTX Position: Q2 2026 in Review

SEI Investments reduced its Avalo Therapeutics (AVTX) stake by 68% in Q2 2026, selling an estimated $615K and leaving 17,931 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #2818.

SEI Investments first reported a position in AVTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $849K in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • SEI Investments held 17,931 shares of Avalo Therapeutics worth $331K as of Q2 2026.
  • SEI Investments sold 38,923 Avalo Therapeutics shares in Q2 2026, an estimated $615K.
  • Avalo Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2818 holding.
  • SEI Investments first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • SEI Investments's Avalo Therapeutics position peaked at $849K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.